Scarica l'app Stockscreener
43.10
15.03%
5.63
Pre-mercato:
44.00
0.90
+2.09%
Precedente Chiudi:
$37.47
Aprire:
$38.33
Volume 24 ore:
2.97M
Relative Volume:
0.98
Capitalizzazione di mercato:
$5.47B
Reddito:
$638.78M
Utile/perdita netta:
$-22.66M
Rapporto P/E:
-247.13
EPS:
-0.1744
Flusso di cassa netto:
$122.18M
1 W Prestazione:
+10.48%
1M Prestazione:
+40.90%
6M Prestazione:
+110.65%
1 anno Prestazione:
+256.20%
Intervallo 1D:
$38.33
$43.10
Intervallo di 1 settimana:
$35.12
$43.10
Portata 52W:
$11.16
$43.10
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
43.10 | 5.47B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
189.70 | 30.82B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
71.58 | 14.05B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
61.50 | 11.04B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
94.81 | 7.93B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
89.92 | 6.96B | 646.34M | -512.40M | 202.76M | -6.6871 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Iniziato | Piper Sandler | Neutral |
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
Does 10x Genomics (TXG) Leaving Russell Value Indexes Reframe Its Growth Versus Profitability Story? - Yahoo Finance
TXG Stock Climbs As Wall Street Hikes Price Targets - StocksToTrade
Is 10x Genomics (TXG) Overvalued Following Its Earnings Beat? - Yahoo Finance
10x Genomics stock hits 52-week high at 40.65 USD - Investing.com
10x Genomics stock hits 52-week high at 40.65 USD By Investing.com - Investing.com India
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $32.08, Implies 14% Downside - TradingView
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG) - TradingView
Price to sales forward of 10x Genomics Inc Class A – SWB:1KJ - TradingView
Enterprise value to revenue forward of 10x Genomics Inc Class A – SWB:1KJ - TradingView
Enterprise value to EBIT forward of 10x Genomics Inc Class A – SWB:1KJ - TradingView
ETFs Investing in 10x Genomics Inc Class A Stocks - TradingView
What Does 10x Genomics' (TXG) Russell Value Index Exit Reveal About Its Evolving Investor Base? - simplywall.st
1KJ Forecast — Price Target — Prediction for 2027 - TradingView
Piper Sandler raises 10X Genomics stock price target on clinical pivot - Investing.com UK
10x Genomics stock hits 52-week high at 37.58 USD - Investing.com
Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS Insider - GlobeNewswire Inc.
10x Genomics, Inc.(NasdaqGS: TXG) dropped from Russell 3000 Value Benchmark - marketscreener.com
10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ) - TradingView
10x Genomics, Inc.(NasdaqGS: TXG) dropped from Russell 3000E Value Benchmark - marketscreener.com
10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ) - TradingView
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor - Yahoo Finance
Price to earnings forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ) - TradingView
Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG) - TradingView
Enterprise value to EBIT forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10X Genomics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
10x Genomics Inc Class A Actuals & Estimates (LSE:0A88) - TradingView
Enterprise value to EBITDA forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (BIVA:TXG) - TradingView
Price to sales forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
TXG Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com - Investing.com Australia
Form 4 10X Genomics Inc For: 24 June By Investing.com - Investing.com Australia
10x genomics CEO Serge Saxonov sells $1.03m in stock - Investing.com
10x Genomics Insider Sold Shares Worth $1,033,269, According to a Recent SEC Filing - marketscreener.com
10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan - Stock Titan
Why Is 10x Genomics (TXG) Stock Soaring Today - Yahoo Finance
Price to book forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10X Genomics stock hits 52-week high at 36.0 USD By Investing.com - Investing.com Australia
10X Genomics stock hits 52-week high at 36.0 USD - Investing.com
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics - Zacks Investment Research
10x Genomics boosts single cell proteomics with acquisition of Proteintech Genomics - SelectScience
Insider Sell: Shehnaaz Suliman Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades - Stock Titan
TXG - Finviz
10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration - BioPharma APAC
10X Genomics stock rises on Cleveland Clinic partnership - Investing.com
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - BioSpace
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):